Research programme: oncolytic virus therapies - Transgene/Randox

Drug Profile

Research programme: oncolytic virus therapies - Transgene/Randox

Alternative Names: Anticancer virus therapies - Randox/Transgene; Anticancer virus therapies - Transgene/Randox; Oncolytic immunotherapies - Randox/Transgene; Oncolytic immunotherapies - Transgene/Randox; Oncolytic virotherapies - Randox/Transgene; Oncolytic virotherapies - Transgene/Randox

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Randox; Transgene
  • Developer Transgene
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 02 Oct 2017 Transgene and Randox enter into a collaboration agreement to develop oncolytic virotherapies for Solid tumors
  • 02 Oct 2017 Early research in Solid tumours in France (IV)
  • 02 Oct 2017 Early research in Solid tumours in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top